Case Study of High-Throughput Drug Screening and Remote Data Collection for SARS-CoV-2 Main Protease by Using Serial Femtosecond X-ray Crystallography
Ömür GüveniD, Mehmet GüliD, Esra Beyarslan AyaniD, J Austin JohnsoniD, Barış ÇakilkayaiD, Gozde Usta, Fatma Betül ErtemiD, Nurettin TokayiD, Büşra YükseliD, Oktay GöcenleriD, Cengizhan BüyükdağiD, Sabine BothaiD, Gihan K. KetawalaiD, Zhen SuiD, Brandon Hayes, Frédéric PoiteviniD, A. BatyukiD, Chun Hong YooniD, Christopher J. KupitziD, Serdar DurdağıiD, Raymond G. SierraiD, Hasan DeMi̇rci̇iD
Abstract
Since early 2020, COVID-19 has grown to affect the lives of billions globally. A worldwide investigation has been ongoing for characterizing the virus and also for finding an effective drug and developing vaccines. As time has been of the essence, a crucial part of this research has been drug repurposing; therefore, confirmation of in-silico drug screening studies has been carried out for this purpose. Here we demonstrated the possibility of screening a variety of drugs efficiently by leveraging a high data collection rate of 120 images/second with the new low-noise, high dynamic range ePix10k2M Pixel Array Detector installed at the Macromolecular Femtosecond Crystallography (MFX) instrument at the Linac Coherent Light Source (LCLS). The X-ray Free-Electron Laser (XFEL) is used for remote high-throughput data collection for drug repurposing of the main protease (Mpro) of SARS-CoV-2 at ambient temperature with mitigated X-ray radiation damage. We obtained multiple structures soaked with 9 drug candidate molecules in two crystal forms. Although our drug binding attempts failed, we successfully established a high-throughput Serial Femtosecond X-ray crystallographic (SFX) data collection protocol.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 8
- FWCI
- 0.53
- Field percentile
- top 44%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Near-Physiological-Temperature Serial Femtosecond X-ray Crystallography Reveals Novel Conformations of SARS-CoV-2 Main Protease Active Site for Improved Drug Repurposing
S. Durdagi, C. Dag, … Sn·bioRxiv·Sep 9, 2020
- Inhibition of SARS-CoV-2 main protease by allosteric drug-binding
S. Guenther, P. Y. A. Reinke, … Schwi·bioRxiv·Nov 12, 2020
- High Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Non-Covalent Inhibitor
A. Clyde, S. Galanie, … R. Stevens·bioRxiv·Mar 27, 2021
- Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
A. Douangamath, D. Fearon, … M. A. Walsh·bioRxiv·May 27, 2020
- Repurposing low-molecular-weight drugs against the main protease of severe acute respiratory syndrome coronavirus 2
- Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug Carmofur